Novartis’ China Revenues Climb 36% in 2009

Novartis AG, the Swiss multinational pharma, said revenues in China grew 36% last year, far better than the company’s overall 11% rise in sales. In 2009, Novartis China was helped by supplying 100 million doses of the company’s A(H1N1) pandemic vaccine to China. Novartis China markets pharmaceuticals, vaccines, and diagnostics. More details... Stock Symbol: (NYSE: NVS)